Table 1 Selected clinical trials using PD-1 disrupted CAR T cells against solid tumors (from clinicalTrials.gov)
From: Hurdles to breakthrough in CAR T cell therapy of solid tumors
NCT number | Title of study | Types of tumor | Interventions | Phase | Status |
|---|---|---|---|---|---|
NCT04768608 | PD1 integrated anti-PSMA CAR T in treating patients with castrate-resistant prostate cancer | Castrate-Resistant Prostate Cancer | PD1-PSMA-CART cells | Phase 1 | Not yet recruiting |
NCT03030001 | PD-1 antibody expressing CAR T cells for mesothelin positive advanced malignancies | Solid Tumor, Adult | PD-1 antibody expressing mesothelin-specific CAR-T cells | Phase 1 | Unknown |
| Â | Â | Advanced Cancer | Â | Phase 2 | Â |
NCT03179007 | CTLA-4 and PD-1 antibodies expressing MUC1-CAR-T cells for MUC1 positive advanced solid tumor | Advanced Solid Tumor | Anti-CTLA-4/PD-1 expressing MUC1-CAR-T | Phase 1 | Unknown |
| Â | Â | Â | Â | Phase 2 | Â |
NCT03615313 | PD-1 antibody expressing mesoCAR-T cells for mesothelin positive advanced solid tumor | Advanced Solid Tumor | PD-1 antibody expressing mesoCAR-T cells | Phase 1 | Unknown |
| Â | Â | Â | Â | Phase 2 | Â |
NCT04489862 | αPD1-MSLN-CAR T cells for the treatment of MSLN-positive advanced solid tumors | Non-small-cell Lung Cancer | αPD1-MSLN-CAR T cells | Early Phase 1 | Recruiting |
| Â | Â | Mesothelioma | Â | Â | Â |
NCT03726515 | CART-EGFRvIII + Pembrolizumab in GBM | Glioblastoma | CART-EGFRvIII T cells + Pembrolizumab | Phase 1 | Completed |
NCT03747965 | Study of PD-1 gene-knocked out mesothelin-directed CAR-T cells with the conditioning of PC in mesothelin positive multiple solid tumors | Solid Tumor, Adult | Mesothelin-directed CAR-T cells | Phase 1 | Unknown |
NCT03545815 | Study of CRISPR-Cas9 mediated PD-1 and TCR gene-knocked out mesothelin-directed CAR-T cells in patients with mesothelin positive multiple solid tumors | Solid Tumor, Adult | anti-mesothelin CAR-T cells | Phase 1 | Recruiting |